Logo image of ALESE.PA

ENTECH SACA (ALESE.PA) Stock Fundamental Analysis

EPA:ALESE - FR0014004362 - Common Stock

7.7 EUR
-0.12 (-1.53%)
Last: 9/5/2025, 7:00:00 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ALESE. ALESE was compared to 42 industry peers in the Construction & Engineering industry. ALESE has a great financial health rating, but its profitability evaluates not so good. ALESE is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

ALESE had negative earnings in the past year.
In the past year ALESE had a positive cash flow from operations.
In the past 5 years ALESE reported 4 times negative net income.
ALESE had a negative operating cash flow in each of the past 5 years.
ALESE.PA Yearly Net Income VS EBIT VS OCF VS FCFALESE.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -5.81%, ALESE is doing worse than 90.48% of the companies in the same industry.
With a Return On Equity value of -11.36%, ALESE is not doing good in the industry: 90.48% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -5.81%
ROE -11.36%
ROIC N/A
ROA(3y)-2.34%
ROA(5y)-0.87%
ROE(3y)-4.85%
ROE(5y)-2.97%
ROIC(3y)N/A
ROIC(5y)N/A
ALESE.PA Yearly ROA, ROE, ROICALESE.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

ALESE has a Gross Margin of 42.82%. This is comparable to the rest of the industry: ALESE outperforms 59.52% of its industry peers.
ALESE's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ALESE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.07%
GM growth 5YN/A
ALESE.PA Yearly Profit, Operating, Gross MarginsALESE.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 40 60

7

2. Health

2.1 Basic Checks

ALESE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALESE remains at a similar level compared to 1 year ago.
Compared to 1 year ago, ALESE has a worse debt to assets ratio.
ALESE.PA Yearly Shares OutstandingALESE.PA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M
ALESE.PA Yearly Total Debt VS Total AssetsALESE.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 3.92 indicates that ALESE is not in any danger for bankruptcy at the moment.
ALESE's Altman-Z score of 3.92 is amongst the best of the industry. ALESE outperforms 88.10% of its industry peers.
The Debt to FCF ratio of ALESE is 1.00, which is an excellent value as it means it would take ALESE, only 1.00 years of fcf income to pay off all of its debts.
ALESE has a Debt to FCF ratio of 1.00. This is amongst the best in the industry. ALESE outperforms 83.33% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that ALESE is not too dependend on debt financing.
ALESE has a better Debt to Equity ratio (0.08) than 88.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 1
Altman-Z 3.92
ROIC/WACCN/A
WACC7.48%
ALESE.PA Yearly LT Debt VS Equity VS FCFALESE.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

ALESE has a Current Ratio of 1.94. This is a normal value and indicates that ALESE is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.94, ALESE belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
A Quick Ratio of 1.81 indicates that ALESE should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.81, ALESE belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.81
ALESE.PA Yearly Current Assets VS Current LiabilitesALESE.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

7

3. Growth

3.1 Past

The earnings per share for ALESE have decreased strongly by -294.30% in the last year.
Looking at the last year, ALESE shows a very strong growth in Revenue. The Revenue has grown by 32.45%.
Measured over the past years, ALESE shows a very strong growth in Revenue. The Revenue has been growing by 68.95% on average per year.
EPS 1Y (TTM)-294.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.33%
Revenue 1Y (TTM)32.45%
Revenue growth 3Y68.95%
Revenue growth 5YN/A
Sales Q2Q%43.81%

3.2 Future

The Earnings Per Share is expected to grow by 119.47% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALESE will show a very strong growth in Revenue. The Revenue will grow by 38.17% on average per year.
EPS Next Y104.76%
EPS Next 2Y146.89%
EPS Next 3Y119.47%
EPS Next 5YN/A
Revenue Next Year42.47%
Revenue Next 2Y51.97%
Revenue Next 3Y42.05%
Revenue Next 5Y38.17%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALESE.PA Yearly Revenue VS EstimatesALESE.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ALESE.PA Yearly EPS VS EstimatesALESE.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 0.4 0.6 0.8

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALESE. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 17.39, ALESE is valued on the expensive side.
Based on the Price/Forward Earnings ratio, ALESE is valued a bit more expensive than 66.67% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.69. ALESE is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 17.39
ALESE.PA Price Earnings VS Forward Price EarningsALESE.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

ALESE's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. ALESE is cheaper than 69.05% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.19
EV/EBITDA N/A
ALESE.PA Per share dataALESE.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

ALESE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALESE's earnings are expected to grow with 119.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y146.89%
EPS Next 3Y119.47%

0

5. Dividend

5.1 Amount

No dividends for ALESE!.
Industry RankSector Rank
Dividend Yield N/A

ENTECH SACA

EPA:ALESE (9/5/2025, 7:00:00 PM)

7.7

-0.12 (-1.53%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners11.98%
Inst Owner ChangeN/A
Ins Owners63.72%
Ins Owner ChangeN/A
Market Cap113.04M
Analysts86
Price Target11.63 (51.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.24%
PT rev (3m)2.24%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-92.86%
EPS NY rev (3m)-92.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.39
P/S 2.49
P/FCF 8.19
P/OCF 7.31
P/B 4.39
P/tB 5.71
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)0.44
Fwd EY5.75%
FCF(TTM)0.94
FCFY12.22%
OCF(TTM)1.05
OCFY13.69%
SpS3.1
BVpS1.75
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.81%
ROE -11.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.82%
FCFM 30.37%
ROA(3y)-2.34%
ROA(5y)-0.87%
ROE(3y)-4.85%
ROE(5y)-2.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.07%
GM growth 5YN/A
F-Score4
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 1
Debt/EBITDA N/A
Cap/Depr 226.86%
Cap/Sales 3.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.81
Altman-Z 3.92
F-Score4
WACC7.48%
ROIC/WACCN/A
Cap/Depr(3y)285.26%
Cap/Depr(5y)212.15%
Cap/Sales(3y)7.1%
Cap/Sales(5y)9.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-294.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.33%
EPS Next Y104.76%
EPS Next 2Y146.89%
EPS Next 3Y119.47%
EPS Next 5YN/A
Revenue 1Y (TTM)32.45%
Revenue growth 3Y68.95%
Revenue growth 5YN/A
Sales Q2Q%43.81%
Revenue Next Year42.47%
Revenue Next 2Y51.97%
Revenue Next 3Y42.05%
Revenue Next 5Y38.17%
EBIT growth 1Y-189.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year317.14%
EBIT Next 3Y118.68%
EBIT Next 5Y103.56%
FCF growth 1Y236.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y273.44%
OCF growth 3YN/A
OCF growth 5YN/A